U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving its shares more than 40 percent lower on Friday.
Original Article: ImmunoGen drug fails cancer study, shares slide 40 percent